Bausch Health Companies Inc. (NYSE:BHC) Receives Average Recommendation of “Hold” from Analysts

Bausch Health Companies Inc. (NYSE:BHC) has been assigned a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $7.75.

A number of research firms have recently weighed in on BHC. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Evercore ISI upgraded shares of Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. Finally, Royal Bank of Canada lifted their target price on shares of Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research report on Friday, November 1st.

Bausch Health Companies Stock Up 1.3 %

BHC stock opened at $7.58 on Thursday. Bausch Health Companies has a 12 month low of $3.96 and a 12 month high of $11.46. The firm has a market cap of $2.74 billion, a P/E ratio of -15.79 and a beta of 0.69. The company’s 50-day moving average price is $8.03 and its two-hundred day moving average price is $7.44.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The company had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period last year, the company posted $1.03 EPS. The firm’s quarterly revenue was up 12.2% compared to the same quarter last year. Equities analysts predict that Bausch Health Companies will post 3.74 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Goldentree Asset Management LP raised its holdings in Bausch Health Companies by 31.0% during the 3rd quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock worth $239,552,000 after purchasing an additional 6,958,717 shares during the last quarter. Bank of Montreal Can increased its stake in shares of Bausch Health Companies by 234.0% in the 3rd quarter. Bank of Montreal Can now owns 3,833,179 shares of the company’s stock valued at $31,598,000 after acquiring an additional 2,685,675 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Bausch Health Companies by 12.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,165,512 shares of the company’s stock valued at $22,063,000 after acquiring an additional 341,936 shares in the last quarter. Mackenzie Financial Corp increased its stake in shares of Bausch Health Companies by 111.0% in the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock valued at $16,612,000 after acquiring an additional 1,252,834 shares in the last quarter. Finally, Maple Rock Capital Partners Inc. bought a new stake in shares of Bausch Health Companies in the 3rd quarter valued at $16,850,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.